Regulatory T cells in acute myelogenous leukemia: Is it time for immunomodulation?

Celalettin Ustun, Jeffrey S. Miller, David H. Munn, Daniel J. Weisdorf, Bruce R. Blazar

Research output: Contribution to journalReview article

95 Citations (Scopus)

Abstract

The microenviroment of acute myelogenous leukemia (AML) is suppressive for immune effector cells. Regulatory T cells (Tregs) have been recognized as a contributor factor and may be recruited and exploited by leukemic cells to evade immunesurveillance. Studies have shown that the frequencies of marrow and blood Tregs are greater in patients with AML than in control patients. Although increased Tregs have been associated with a decreased risk of GVHD after allogeneic HCT and hence may impede the graft-versus-tumor effect, recent findings indicate that that this may not be the case. Because there is a need to improve outcomes of standard treatment (chemotherapy with or without allogeneic HCT) in AML, targeting Tregs present an outstanding opportunity inAML because discoveries may apply throughout its treatment. Here, we review data on the roles of Tregs in mediating immune system-AML interactions. We focused on in vitro, animal, and observational human studies of Tregs inAML biology, development, prognosis, and therapy in different settings (eg, vaccination and HCT). Manipulation of Tregs or other types of immunomodulation may become a part of AML treatment in the future.

Original languageEnglish (US)
Pages (from-to)5084-5095
Number of pages12
JournalBlood
Volume118
Issue number19
DOIs
StatePublished - Nov 10 2011

Fingerprint

Chemotherapy
T-cells
Immunomodulation
Immune system
Regulatory T-Lymphocytes
Acute Myeloid Leukemia
Grafts
Tumors
Animals
Blood
Observational Studies
Immune System
Vaccination
Therapeutics
Bone Marrow
Transplants
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Regulatory T cells in acute myelogenous leukemia : Is it time for immunomodulation? / Ustun, Celalettin; Miller, Jeffrey S.; Munn, David H.; Weisdorf, Daniel J.; Blazar, Bruce R.

In: Blood, Vol. 118, No. 19, 10.11.2011, p. 5084-5095.

Research output: Contribution to journalReview article

Ustun, Celalettin ; Miller, Jeffrey S. ; Munn, David H. ; Weisdorf, Daniel J. ; Blazar, Bruce R. / Regulatory T cells in acute myelogenous leukemia : Is it time for immunomodulation?. In: Blood. 2011 ; Vol. 118, No. 19. pp. 5084-5095.
@article{41293b7fdc064a0faba3df0114c3792c,
title = "Regulatory T cells in acute myelogenous leukemia: Is it time for immunomodulation?",
abstract = "The microenviroment of acute myelogenous leukemia (AML) is suppressive for immune effector cells. Regulatory T cells (Tregs) have been recognized as a contributor factor and may be recruited and exploited by leukemic cells to evade immunesurveillance. Studies have shown that the frequencies of marrow and blood Tregs are greater in patients with AML than in control patients. Although increased Tregs have been associated with a decreased risk of GVHD after allogeneic HCT and hence may impede the graft-versus-tumor effect, recent findings indicate that that this may not be the case. Because there is a need to improve outcomes of standard treatment (chemotherapy with or without allogeneic HCT) in AML, targeting Tregs present an outstanding opportunity inAML because discoveries may apply throughout its treatment. Here, we review data on the roles of Tregs in mediating immune system-AML interactions. We focused on in vitro, animal, and observational human studies of Tregs inAML biology, development, prognosis, and therapy in different settings (eg, vaccination and HCT). Manipulation of Tregs or other types of immunomodulation may become a part of AML treatment in the future.",
author = "Celalettin Ustun and Miller, {Jeffrey S.} and Munn, {David H.} and Weisdorf, {Daniel J.} and Blazar, {Bruce R.}",
year = "2011",
month = "11",
day = "10",
doi = "10.1182/blood-2011-07-365817",
language = "English (US)",
volume = "118",
pages = "5084--5095",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",

}

TY - JOUR

T1 - Regulatory T cells in acute myelogenous leukemia

T2 - Is it time for immunomodulation?

AU - Ustun, Celalettin

AU - Miller, Jeffrey S.

AU - Munn, David H.

AU - Weisdorf, Daniel J.

AU - Blazar, Bruce R.

PY - 2011/11/10

Y1 - 2011/11/10

N2 - The microenviroment of acute myelogenous leukemia (AML) is suppressive for immune effector cells. Regulatory T cells (Tregs) have been recognized as a contributor factor and may be recruited and exploited by leukemic cells to evade immunesurveillance. Studies have shown that the frequencies of marrow and blood Tregs are greater in patients with AML than in control patients. Although increased Tregs have been associated with a decreased risk of GVHD after allogeneic HCT and hence may impede the graft-versus-tumor effect, recent findings indicate that that this may not be the case. Because there is a need to improve outcomes of standard treatment (chemotherapy with or without allogeneic HCT) in AML, targeting Tregs present an outstanding opportunity inAML because discoveries may apply throughout its treatment. Here, we review data on the roles of Tregs in mediating immune system-AML interactions. We focused on in vitro, animal, and observational human studies of Tregs inAML biology, development, prognosis, and therapy in different settings (eg, vaccination and HCT). Manipulation of Tregs or other types of immunomodulation may become a part of AML treatment in the future.

AB - The microenviroment of acute myelogenous leukemia (AML) is suppressive for immune effector cells. Regulatory T cells (Tregs) have been recognized as a contributor factor and may be recruited and exploited by leukemic cells to evade immunesurveillance. Studies have shown that the frequencies of marrow and blood Tregs are greater in patients with AML than in control patients. Although increased Tregs have been associated with a decreased risk of GVHD after allogeneic HCT and hence may impede the graft-versus-tumor effect, recent findings indicate that that this may not be the case. Because there is a need to improve outcomes of standard treatment (chemotherapy with or without allogeneic HCT) in AML, targeting Tregs present an outstanding opportunity inAML because discoveries may apply throughout its treatment. Here, we review data on the roles of Tregs in mediating immune system-AML interactions. We focused on in vitro, animal, and observational human studies of Tregs inAML biology, development, prognosis, and therapy in different settings (eg, vaccination and HCT). Manipulation of Tregs or other types of immunomodulation may become a part of AML treatment in the future.

UR - http://www.scopus.com/inward/record.url?scp=81055148087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81055148087&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-07-365817

DO - 10.1182/blood-2011-07-365817

M3 - Review article

C2 - 21881045

AN - SCOPUS:81055148087

VL - 118

SP - 5084

EP - 5095

JO - Blood

JF - Blood

SN - 0006-4971

IS - 19

ER -